Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2009-016947-20-CZ
EUCTR2009-016947-20-CZActive, not recruitingPhase 1

A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

Seattle Genetics, Inc.0 sites322 target enrollmentStarted: March 26, 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
322
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1.Patients with HL who have received ASCT in the previous 30–45 days.
  • •2. Patients at high risk of residual HL post ASCT as indicated by at least one of the following criteria. Patients prematurely discontinuing planned frontline therapy for reasons other than disease progression are not considered high risk.
  • •-History of refractory HL (defined as patients progressing on or failing to achieve a complete remission following frontline standard chemotherapy or a combined modality treatment program)
  • •-Relapsed or progressive HL that occurs <12 months from the end of frontline standard chemotherapy or a combined modality treatment program
  • •- Extranodal involvement at the time of pre-ASCT relapse (including extranodal extension of nodal masses into adjacent vital organs)
  • •3. Histologically-confirmed classical HL, which excludes NLPHL.
  • •4. Age greater than or equal to 18 years.
  • •5. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • •6. The following required baseline laboratory data: absolute neutrophil count (ANC) =1000/µL, platelets =50,000/µL (unsupported), bilirubin =1.5X upper limit of normal (ULN) or =3X ULN for patients with Gilbert’s disease, serum creatinine =1.5X ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5X ULN.
  • •7. Females of childbearing potential must have a negative serum or urine ß-hCG pregnancy test result within 7 days prior to the first dose of SGN-35. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a
  • •bilateral tubal ligation or hysterectomy.
  • •8. Both females of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug.
  • •9. Patients or their legally authorized representative must provide written informed consent.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range: 0
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 311
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 11

Exclusion Criteria

  • •1. Previous treatment with SGN-35.
  • •2. Previously received an allogeneic transplant.
  • •3. Patients who were determined to have a best clinical response of progressive disease with salvage treatment immediately prior to ASCT.
  • •4. History of another primary malignancy that has not been in remission for at least 3 years. (The following are exempt from the 3-year limit: nonmelanoma skin cancer, fully excised melanoma in situ [Stage 0], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear.)
  • •5. Known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy (PML).
  • •6. Any Grade 3 or higher active infection within 1 week prior to first study dose.
  • •7. Post ASCT or current therapy with other systemic anti-neoplastic or investigational agents.
  • •8. Women who are pregnant or lactating.
  • •9. Patients with a known hypersensitivity to any excipient contained in the drug formulation.
  • •10. Patients with dementia or an altered mental state that would preclude the understanding and rendering of informed consent.

Investigators

Sponsor
Seattle Genetics, Inc.

Similar Trials

Recruiting
Phase 1
A study to determine the safety, tolerability and pharmacokinetics of ZYAN1 following oral administration in healthy volunteers.Anemia
ACTRN12614001240639Cadila Healthcare Limited100
Active, not recruiting
Phase 1
Darolutamide in addition to standard hormone therapy and docetaxel in metastatic hormone-sensitive prostate cancerMetastatic hormone-sensitive prostate cancer (mHSPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-002590-38-BGBayer AG1,300
Active, not recruiting
Phase 1
Darolutamide in addition to standard hormone therapy and docetaxel in metastatic hormone-sensitive prostate cancer
EUCTR2015-002590-38-FIBayer AG1,300
Unknown
Phase 1
A clinical study toevaluate the safety, tolerability and pharmacokinetics of oral ZYGK1 in healthy volunteers
CTRI/2011/12/002249Zydus Research Centre96
Active, not recruiting
Not Applicable
A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After Chemotherapy.
EUCTR2010-024468-16-CZF. Hoffmann-La Roche Ltd610